Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;28(4):790-801.
doi: 10.3350/cmh.2022.0070. Epub 2022 May 11.

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng  1 , Daniel Q Huang  1   2 , Mindie H Nguyen  3   4
Affiliations
Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng et al. Clin Mol Hepatol. 2022 Oct.

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis and the absence of other causes of liver disease. As NAFLD is closely associated with the presence of the metabolic syndrome, several experts have called for a change in nomenclature from NAFLD to metabolic-associated fatty liver disease (MAFLD) to better reflect the underlying pathophysiology of NAFLD as a metabolically driven disease and shift to a "positive" diagnostic criteria rather than one of exclusion. Recent studies have suggested that the global prevalence of MAFLD is higher than that of NAFLD, and patients with MAFLD have more metabolic comorbidities compared to those with NAFLD. Emerging data also suggest that all-cause and cardiovascular mortality may be higher in MAFLD compared with NAFLD. In this synopsis, we discuss differences in clinical features, prevalence and clinical outcomes between NAFLD and MAFLD. In addition, we highlight the advantages and disadvantages of a name change from NAFLD to MAFLD from the perspective of the scientific community, care providers and patients.

Keywords: Liver, Nonalcoholic fatty; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Mindie H. Nguyen: Research support: Pfizer, Enanta, Gilead, Glycotest, Vir, B.K. Kee Foundation, National Cancer Institute. Advisory board/consulting: Janssen, Spring Bank, Gilead, Novartis, Bayer, Eisai, Eli Lilly, Exact Sciences, Laboratory of Advanced Medicine, Helio Health, Intercept.

Daniel Q. Huang: Research support: Exxon Mobil-NUS Research Fellowship for Clinicians, NMRC Research Training Fellowship. Advisory board/consulting: Eisai.

Other authors have no disclosures.

Figures

Figure 1.
Figure 1.
Graphical illustration of groups included in the analysis of overlapping conditions. MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease.
Figure 2.
Figure 2.
Graphical illustration of groups included in the analysis of non-overlapping conditions. MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease.
Figure 3.
Figure 3.
Advantages and disadvantages of a change in name from NAFLD to MAFLD. MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. - PubMed
    1. Fleming KA, Morton JA, Barbatis C, Burns J, Canning S, McGee JO. Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant. Gut. 1981;22:341–344. - PMC - PubMed
    1. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021 Dec 7; doi: 10.1016/j.cgh.2021.12.002. doi: - DOI - PubMed
    1. Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021 Dec 4; doi: 10.1016/j.cgh.2021.11.038. doi: - DOI - PubMed
    1. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398. - PubMed

MeSH terms